UNLIMITED TURBO SHORT - AMGEN | Delayed Deutsche Boerse AG 09:35:29 2024-07-11 am EDT | ||
| 2.88 EUR | -1.71% |
|
| Current month | -21.87% | ||
| 1 month | -35.60% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
AMGEN INC.
Latest news about AMGEN INC.
| Date | Price | Change |
|---|---|---|
| 24-07-11 | 2.88 | -1.71% |
| 24-07-10 | 2.93 | -15.56% |
| 24-07-09 | 3.47 | -9.87% |
| 24-07-08 | 3.85 | -0.77% |
| 24-07-05 | 3.88 | -4.43% |
Delayed Quote Deutsche Boerse AG
Last update July 11, 2024 at 09:35 am EDT
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | AMGEN INC. |
| Issuer | 
BNP Paribas
|
| WKN | PE4K6B |
| ISIN | DE000PE4K6B3 |
| Date issued | 2022-10-28 |
| Strike | 351 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 9.27 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 13.4 € |
|---|---|
| Lowest since issue | 2.51 € |
Company Profile
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
-
Consensus: Amgen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
321.7
USD
Average target price
316.1
USD
Spread / Average Target
-1.72%
- Stock Market
- Certificates
- Certificat
